Innerva Pharmaceuticals develops a novel ophthalmic formulation targeting ocular pain associated with dry eye and other surface ocular diseases. Its lead candidate, licensed from the University of Tennessee Research Foundation, reduces pain by blocking the PIEZO2 ion channel in mechanosensitive nociceptor nerve endings. The company aims to advance the candidate through formulation work toward a human clinical trial. Innerva was founded in Barcelona in 2022 by Patrick Tresserras and Professor Carlos Belmonte. The financing announced will support preclinical formulation development and a strategy to secure non‑dilutive funding to align partner interests and reach clinical testing. The company positions its approach to address post‑surgical and chronic surface ocular pain as well as dry eye, areas with unmet medical need.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2022